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Abstract  
Background  
To examine the impact of multimodal (MMS) and ultrasound (USS) screening on the 
sexual activity and functioning of 22,966 women in the UK Collaborative Trial of 
Ovarian Cancer Screening (UKCTOCS) RCT.  
 
Methods  
Fallowfield’s Sexual Activity Questionnaire (FSAQ) was completed prior to 
randomisation, then annually in a random sample (RS) of women from MMS, USS 
and control groups. Any women in the study who required repeat screening due to 
unsatisfactory results formed an Events Sample (ES); they completed questionnaires 
following an event and annually thereafter.   
 
Results  
Over time in the RS (n=1,339) there was no difference between the MMS and USS 
groups in sexual activity compared with controls. In the ES there were significant 
differences between the USS group (n=10,156) and the MMS group (n=12,810). The 
USS group had lower pleasure scores (mean difference = -0.14, P=0.046). For both 
groups women who had ≥2 repeat screens, showed a decrease in mean pleasure 
scores compared to their annual scores (mean difference = -0.16, P=0.005). Similarly 
mean pleasure scores decreased following more intensive screens compared to 
annual screening (mean difference= -0.09, P=0.046).  
 
Conclusion 
Ovarian cancer screening did not affect sexual activity and functioning unless a 
woman had abnormal results and underwent repeated or higher level screening.  
 
Key Words: Ovarian cancer screening; sexual activity, Fallowfield’s sexual activity 
questionnaire, UKCTOCS 
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Background 
Prior to the introduction of any National screening programme it is important to 
establish that any of the benefits shown from a well-conducted randomised 
controlled trial, are weighed against any potential harms of screening. Furthermore 
individuals invited to join such programmes must be provided with information that 
allows them to weigh up all these harms and benefits according to their own values 
and preferences to enable informed decisions about attendance. 
The UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) is a large 
randomised trial involving 13 UK centres and over 202,000 postmenopausal women. 
The primary aim is to assess the effect of screening on disease mortality. Volunteers 
were randomised to annual multimodal screening (MMS) with serum CA125 
interpreted using the risk of ovarian cancer algorithm (ROCA), annual transvaginal 
ultrasound screening (USS), or no screening (control), in a 1:1:2 ratio (Skates et al, 
2001; Menon et al, 2005). Preliminary results showed a significant mortality 
reduction with MMS when prevalent cases were excluded, but further follow up is 
warranted before firm conclusions can be made about the efficacy and cost 
effectiveness of population screening (Jacobs et al, 2016).  
The benefits of screening in terms of early detection and possibility of more effective 
treatment are well-elucidated, the many putative harms less so. While in other 
cancer screening programmes, such as those for cervical and breast cancer, false-
positive results led to a high level of anxiety, little is known about the reactions of 
well women undergoing population screening for ovarian cancer; the sparse 
literature has focused on those with a familial history (Wardle et al, 1993; Fry et al, 
2001). Potential disadvantages of screening for ovarian cancer (OC) include the 
psychosocial costs of unnecessary surgery and other sequelae resulting from the 
screening process itself (Bell et al, 1998). The specificity and sensitivity of the 
process can impact on who presents for screening, their levels of anxiety and 
adherence, and ultimately the detection and mortality rates for the disease 
(Robinson et al, 1997). Many factors impact on how women process or filter the 
information that is presented to them and consequently may impact on levels of 
anxiety, depression and risk perceptions.  Examination therefore of the psychological 
costs and benefits of the different methods of OC screening in a population 
screening study of well women is vital.  
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We have already reported results showing that although OC screening as such did 
not appear to raise anxiety, psychological morbidity was elevated by more intrusive 
repeat testing involving transvaginal ultrasound following abnormal annual screens, 
and also in women diagnosed with OC (Barrett et al, 2014). In addition, withdrawal 
rates from UKCTOCS for women who required repeat screening were greater in:- 
the USS group compared with the MMS group (20.1% vs 12.9%), those who 
required repeat screens early in the study, individuals with a high predisposition to 
anxiety, and those with high levels of psychological morbidity (Jenkins et al, 2015). 
We now report the effect of ovarian cancer screening on sexual activity and function.  
Sexual dysfunction may result from a complex interplay of psychological, physical 
and interpersonal relationship factors. Screening may affect the balance of these in 
numerous ways. It is known for example that women participating in a screening 
programme for cervical cancer who had abnormal results reported high anxiety 
levels, mood, concentration and psychosexual disturbances. It is uncertain if these 
psychosexual problems result from the screening procedures themselves or from the 
implications of an abnormal result, namely the possibility of a life-threatening disease 
and necessity for unpleasant treatments (Summers A, 1998). Likewise Lerman et al 
(1991) reported the impaired psychosexual functioning of women who had an 
abnormal smear compared with controls. A review by Rogstad (2002) quotes 
Quillam’s views about the psychological impact of abnormal cytology as 
“transforming a well woman with no symptoms into a patient with fears and 
anxieties’. The review showed that virtually all studies revealed that screening was 
associated with significant anxiety and psychosexual sequelae as did another by 
Lewis et al. (2010) who concluded that there is accumulating evidence showing an 
association between anxiety and depression with sexual dysfunction.   
There is less research conducted with women invited for ovarian cancer screening 
but it seems reasonable to infer from other research that learning that an ovarian 
cancer screening test was in some way unsatisfactory and needed repeating might 
raise anxiety which could in turn affect sexual activity. This might be even more 
apparent in women with a high anxiety trait or predisposition towards anxiety.  
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In this current report therefore we examined the effect that different methods of OC 
screening had on sexual activity, specifically:- 
1) If there were differences in sexual activity and functioning between the MMS, USS 
and Control groups that were not explained by anxiety trait levels  
2) If women who underwent multiple screening experienced a decline in sexual 
activity compared to that following annual screening. 
Methods 
The design of UKCTOCS and the psychosocial study has been described in detail 
elsewhere (Menon et al, 2008; Barrett et al, 2014).  The trial involved 202,638 
postmenopausal women recruited through 13 UK centres who were randomised to a 
no screening control group (n=101,359) or annual screening using a serum CA125 
test in the MMS group (n=50,640) or transvaginal ultrasonography (TVS) in the USS 
group (n=50,639).  The psychosocial arm of UKCTOCS was approved by the North 
West MREC committee (ref: MREC 00/8/34). 
 
The blood test for serum CA125 was interpreted using the ROCA; TVS was 
performed by ultra-sonographers. Repeat screens were categorised as either Level I 
or II. Level I screens involved repeating annual screens within 3 months for 
equivocal results that is, ‘intermediate risk’ in the MMS group or ‘unsatisfactory scan’ 
in the USS group. Level II screens were undertaken within six weeks of abnormal 
results and involved for the MMS group a repeat CA125 blood test with ROCA and a 
TVS; those in the USS group had a repeat TVS by a senior ultra-sonographer or 
consultant. Women were sent letters clarifying their results and reasons for repeat 
screens.  
Events in a population screening trial of essentially healthy women are rare which is 
why most research is limited to cross-sectional studies. As a complete psychosocial 
assessment of more than 200,000 women in UKCTOCS for 6 years was not feasible, 
we conducted a partial longitudinal follow-up of a cohort of women in the USS and 
MMS groups who were recalled for at least one repeat screen during their time on 
study (see Consort diagram Fig A). All women had completed questionnaires prior to 
randomisation at baseline and were only followed up in the psychosocial study after 
their first recall, and then annually and/or following subsequent repeat screens, 
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provided no abnormality was found. If an abnormality was confirmed, women were 
referred for a gynaecological oncology opinion with a view to surgery. Those who 
had both their ovaries removed and/or were diagnosed with ovarian (OC) or other 
cancer had no further screening. If no ovaries were removed and no cancer detected 
at surgery, then women could continue in the study.  
 
A further unique feature of the UKCTOCS psychosocial study was identification of a 
random sample (RS) comprising 1339 women from MMS, USS and control groups 
monitored for complete longitudinal follow-up. This sample completed psychosocial 
assessment questionnaires at baseline and following annual screening. In addition to 
providing complete longitudinal follow-up, this allowed comparison of psychosocial 
outcomes between the screened and control groups.  
 
During the psychosocial study period a total 22,966 women from the MMS and USS 
groups in UKCTOCS, including the RS, had at least one repeat screen following 
annual screening post randomisation. This group of women are hereafter referred to 
as the Events Sample (ES). 
 
Assessment measures 
Study specific questionnaires probing participants’ socio-demographic details, 
attitudes and beliefs about ovarian cancer and their satisfaction with screening and 
overall psychological morbidity (Fallowfield et al. 2010) were administered. Women 
also completed the Fallowfield Sexual Activity Questionnaire (FSAQ) (Thirlaway et al, 
1996; Atkins et al, 2007), the Spielberger State/Trait Anxiety Inventory 
(STAI)(Spielberger et al,1983) at each time point. 
 
Fallowfield’s Sexual Activity Questionnaire (FSAQ) 
The FSAQ is a validated and widely used questionnaire designed to measure female 
sexual activity and functioning (Erichsen et al, 2010; Marino et al, 2014; Reif et al, 
2015. da Costa et al, 2016).  The FSAQ consists of three sections: - Section I 
enquires whether or not the woman is sexually active; Section II probes reasons for 
lack of sexual activity by those who are not sexually active; Section III is completed 
only by sexually active women and measures aspects of sexual function as well as 
activity; it has 10 items, which are scored using a Likert format (very much, 
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somewhat, a little, not at all). There are 3 domains: (i) Pleasure (desire, enjoyment, 
satisfaction and frequency; (range 0–18). High scores on this subscale indicate 
greater pleasure resulting from sexual activity; (ii) Discomfort (dryness and pain; 
(range 0–6). Low scores on this subscale indicate greater discomfort during sexual 
activity and (iii) Habit (range 0-3)  indicates the degree to which the frequency of 
sexual activity during the previous month was usual for the respondent – ‘the same’, 
‘not as much’, ‘somewhat’ or ‘much more than usual’). 
 
Spielberger State/Trait Anxiety Inventory (STAI)  
The STAI consists of two questionnaires with 20 items rated on simple 4 point 
scales.  It is a well-known, validated research clinical tool used successfully in many 
studies to evaluate anxiety proneness (Trait) and the current state of anxiety or 
anxiety change (State). 
 
Statistical Methods 
The 2 primary aims of the analyses were 1) to examine differences in sexual activity 
and functioning between USS, MMS and control groups over time that were not 
explained by anxiety trait levels; and 2) to examine the effect of repeat screening and 
level of this screening on changes in sexual activity. Linear mixed effects and mixed 
effects logistic regression models were used for the analysis of the FSAQ Section III 
subscales and individual items. These models extend standard regression analyses 
to account for the correlation between repeated observations from each individual, 
through inclusion of a random intercept.  
The subscale scores for pleasure and discomfort were analysed with linear mixed 
effects regression models with a random intercept.  Habit was recoded as 1 if 
frequency of sexual activity was much more or somewhat more than usual and 0 if it 
was about the same or not as much as usual. Similarly, each individual item of the 
pleasure score (questions 1, 2, 4, 7, 8, 10) was recoded (1= very much, somewhat, 
0= a little, not at all). The individual items of the discomfort score (questions 5, 6) 
were recoded (1= a little, not at all, 0= very much, somewhat). The recoded binary 
variables were analysed using mixed effects logistic regression models with a 
random intercept.  
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The regression models examined mean differences between groups and included 
the following explanatory variables:-an indicator of group (MMS, USS or control), 
baseline age, screening centre and time from baseline represented by calendar year 
quarters to capture any time periods between assessments shorter than a year. 
Baseline anxiety trait (low, medium or high) was included to assess whether any 
differences in sexual functioning may be explained by anxiety trait. An interaction 
term between group indicator and time was added to examine any differential effects 
of group membership on the outcome over time. 
Three sets of analyses were undertaken for the FSAQ Section III subscales and 
individual items, based on data collected at baseline and after (i) annual screens for 
the RS, (ii) annual screens following the first recall for the ES; and (iii) annual 
screens following the first recall and any subsequent repeats for the ES.  The latter 
analyses included the cumulative number of repeat screens (annual, 1, ≥2) and the 
level of these (annual, level I or II) as explanatory variables. These were time-varying 
variables which allowed assessment of the effects of repeat screening and level 
compared to annual screening on a woman’s sexual activity. 
Each of the analyses is of clinical interest on its own right and therefore no 
adjustment was made for multiple hypothesis testing. 
Models were fitted using maximum likelihood estimation, P-values were calculated 
using Wald tests. All analyses were performed using the statistical software R 
packages “glmmML” and “lme4” in R (R Core Team 2005; Broström G, 2013; Bates 
et al, 2015). 
Findings 
The RS comprised 1,339 women whose baseline characteristics are described in 
Table 1 along with those in the ES (n=22,966: USS =10,156 and MMS =12,810). 
Almost half of the women in each sample, 647 in the RS and 11,314 in the ES, 
indicated that they were sexually active at baseline. A similar distribution was 
observed by screening group. Table 2 shows that the most common reason given by 
women who were not sexually active at baseline was “No partner” with responses 
ranging from 32% to 39% across groups and samples. A third of the women in each 
group and sample indicated that they were not interested in sex. Only 8-13% women 
had a physical problem. Table 3 describes baseline frequencies (%) of those women 
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who were ‘somewhat/very much’ sexually active in the RS and ES. The distribution 
of these are similar across groups and samples. Supplementary Tables S1 and S2 
show the mean and median baseline FSAQ subscales by group. There was a 
decline in the number of women who were sexually active over time, with the USS 
and MMS groups showing greater decline than the control group as shown in Tables 
S3 and S4.  
 
Comparison of sexual function between groups over time 
Analysis of annual screen data from the RS who remained sexually active, showed 
no evidence that sexual function (FSAQ Section III) in the screening groups (MMS or 
USS) differed from the control group over time. Estimated mean scores differences 
between MMS and control were -0.05 (P=0.88) and -0.06 (P=0.67) for pleasure and 
discomfort respectively, and OR=0.99 (P=0.98) for habit. When comparing USS with 
control the estimated mean scores differences were 0.03 (P=0.93) and 0.09 (P=0.60) 
for pleasure and discomfort respectively, and OR=1.23 (P=0.38) for habit. Similarly, 
analysis of annual screen data from the ES showed no differences between the 
MMS and USS groups over time. When questionnaires arising from repeat screens 
were incorporated into the analyses, there were no differences across time between 
the USS and MMS groups apart from pleasure (mean score difference = - 0.14, 
P=0.046), which was lower in the USS group over time. There was a moderate 
interaction between group (MMS or USS) and time (year quarters) on pleasure score 
(P=0.09). This showed slightly slower decline on the predicted mean score of 
pleasure in the MMS than in the USS group over time (Figure 1).  
 
Effect of repeat screening and level of screening 
There was no difference in mean pleasure score over time in women having 1 repeat 
screen compared to annual screening (P=0.73). However, women who had ≥2 
screen repeats had lower mean pleasure scores over time compared to annual 
screening (mean score difference = - 0.16, P=0.005) (Table S5). This was explained 
mostly from lower satisfaction (OR=0.87, P=0.07), lower enjoyment (OR=0.82, 
P=0.005) and lower activity (OR=0.77, P<0.001). Those who required Level II 
screens had lower pleasure scores (mean score difference= -0·09, P=0·046) which 
came mostly from lower enjoyment (OR=0.89, P=0.040). 
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Effect of anxiety, age and time 
Women in the ES who had higher levels of trait anxiety at baseline were at higher 
risk of reduced habit (OR=0.57, P<0.001) (see Figure 2), greater discomfort (mean 
score difference= - 0.80, P<0.001) and lower pleasure (mean score difference= -
3.20, P<0.001). Similar effects were observed in women who had repeat screens 
and women in the RS having annual screens (see Figure 3).  
In the ES there was a significant negative effect of age at baseline in pleasure 
scores. Being one year older was associated with a difference in mean pleasure 
score of –0.05 (P<0.001). For example the mean difference between two women 
with 10 year age difference at baseline was – 0.50 (10 x –0.05). Similarly, having sex 
was less important (OR=0.75, P<0.001), there was less enjoyment (OR=0.70, 
P<0.001), less desire (OR=0.68, P<0.001), more dryness (OR=0.78, P<0.001), less 
satisfaction (OR=0.88, P=0.014) and lower frequency of sexual activity (OR=0.37, 
P<0.001). Similar effects were observed when including repeat screens. In the RS 
older age was associated with less enjoyment (OR=0.59, P=0.001) and lower 
frequency (OR=0.42, P<0.001). 
There was deterioration across all FSAQ items over time in both ES and RS. For 
each year that a woman spent in the study, there was a mean change of pleasure 
score of – 0.17 (P<0.001) and – 0.19 (P<0.001); and a mean change in discomfort 
score of -0.05 (P<0.001) and – 0.07 (P<0.001) in the RS and the ES annual screen 
data, respectively. Similarly, there was a higher risk of reduced habit over time, 
OR=0.82, (P<0.001) and OR=0.81 (P<0.001) for the RS and the ES annual screen 
data, respectively. 
Discussion 
Our results show that ovarian cancer screening for postmenopausal women over 50 
years of age in itself does not affect sexual activity and functioning. Overall, women 
experienced a decrease in all aspects of sexual activity across time, as did women 
with a predisposition to high anxiety. Sexual activity was less frequent, not as 
pleasurable and more uncomfortable. Cervical screening studies have shown that 
sexual activity and relationships are affected especially if the woman requires more 
invasive procedures to determine the results (Juraskova et al, 2007). A similar 
pattern was recorded in our study. Sexually active women who had two or more 
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repeat screens had lower pleasure scores over time, as did those who required 
Level II screens involving TVS.  Although women in the screening events sample, 
(MMS and USS) did not differ in sexual activity over time, there were differences in 
sexual functioning; women in the USS group had significantly lower pleasure scores, 
based on frequency, enjoyment, desire and satisfaction.  
The decision as to whether screening is worthwhile depends on the overall benefits 
and harms of screening and the resources required. Screening may result in 
considerable benefits for a small number of people, with larger numbers affected by 
smaller negative effects. There may also be a range of opinions among women and 
health professionals regarding the balance of benefits and risks for which they would 
consider screening valuable. 
A recent systematic review reported that a previous “false-alarm” cancer diagnosis 
delayed future help seeking behaviours for new or recurrent possible cancer 
symptoms, in some cases persisting for months or even years (Renzi et al, 2015). 
We have already reported that the need for repeat screening had an impact on 
withdrawal from the study and psychological morbidity, especially if it resulted 
following abnormal rather than equivocal results. Our current report shows that 
sexual activity is similarly affected. There is therefore a continuing need, irrespective 
of the OC screening strategy, to explore ways to decrease any unnecessary repeat 
screens. Also lower use of transvaginal ultrasound with multimodal screening may 
be less intrusive causing fewer problems. Women with a predisposition to anxiety 
may also require some extra counselling, help and support if they are to adhere to 
any screening programme and not experience adverse psychosocial effects from 
repeat testing.  
The results from this extensive psychosocial study together with the UKCTOCS 
mortality data should be helpful to policy makers deciding whether or not to introduce 
an ovarian cancer population screening programme. 
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Table 1 
Baseline demographics of Random Sample (RS) and Events Sample (ES) 
 
 
 
 
 
 
 
 
 
 
 
NB. 201 women in the RS had at least one event. Therefore, there is an overlap between the RS and the ES for questionnaires completed by 
these women at baseline, and annually following the occurrence of an event. 
 
 
   
 Control  
group 
 
Ultrasound (USS) 
group 
 
Multimodal (MMS) 
group 
 
 RS 
(n=755) 
RS 
(n=283)  
ES 
(n=10156) 
RS 
(n=301) 
ES 
(n=12810) 
Partner: Yes 597 (79.1%) 215 (76%) 7840 (77.2%) 234 (77.7%) 10060 (78.5%) 
Sexually Active 
Yes 
No 
 
373 (49.4%) 
378 (50.1%) 
 
134 (47.3%) 
144 (50.9%) 
 
4971 (48.9%) 
5124 (50.5%) 
 
140 (46.5%) 
159 (52.8%) 
 
6343 (49.5%) 
6389 (49.9%) 
Age at randomisation  
(yrs) mean (sd) 
 
60.86 (6.26) 
 
62.10 (6.56) 
 
60.73 (6.39) 
 
61.75 (6.56) 
 
61.2 (6.27) 
STAI trait anxiety 
Low 
Medium 
High 
 
113 (15.1%) 
511 (68.4%) 
123 (16.5%) 
 
58 (20.8%) 
182(65.2%) 
39(14.0%) 
 
1668 (16.8%) 
6541 (66%) 
1697 (17.1%) 
 
58 (19.3%) 
187 (62.3%) 
55 (18.3%) 
 
2098 (16.8%) 
8341 (66.7%) 
2065 (16.5%) 
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Table 2 Frequency (%) of reasons for lack of sexual activity at baseline in the random sample and events sample 
 Reasons for no sex Random Sample 
 (n=681) 
 
Events Sample 
(n=11,513) 
 
  Control group 
(n=378)1 50% 
USS 
(n=144) 52% 
MM 
(n=159) 53% 
USS 
(n=5,124) 51% 
MM 
(n=6,389) 50% 
A No partner 138 (37%) 53 (37%) 51 (32%) 1973 (39%) 2307 (36%) 
B Too tired 34 (9%) 11 (8%) 18 (11%) 459 (9%) 572 (9%) 
C Partner is tired 31 (8%) 13 (9%) 17 (11%) 382 (7%) 487 (8%) 
D Not interested in sex 111 (29%) 38 (26%) 48 (30%) 1527 (30%) 1933 (30%) 
E Partner not interested  82 (22%) 33 (23%) 37 (23%) 1058 (21%) 1348 (21%) 
F I have a physical problem 48 (13%) 11 (8%) 16 (10%) 573 (11%) 716 (11%) 
G Partner has physical problem 84 (22%) 37 (26%) 47 (30%) 1124 (22%) 1511 (24%) 
H Other reasons 104 (28%) 41 (28%) 53 (33%) 1470 (29%) 1831 (29%) 
                                                          
1 Number of women who were not sexually active, % 
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Table 3 Baseline frequencies (%) of “very much/ somewhat” responses to FSAQ Section III questions of Random Sample (RS) 
(n=647) and Events Sample (ES) (n=11,314) who were sexually active  
 
  Control 
group 
 
USS 
 
MMS 
 
  RS  
(n=373)2 
 50% 
 RS 
(n=134) 
48% 
ES 
(n=4971) 
49%   
RS 
(n=140) 
47% 
ES  
(n=6343) 
50% 
1 Was having sex an important part of your life? 235/3693 
(64%) 
82/130 
(63%) 
2930/4891 
 (60%) 
82/138 
(59%) 
3720/6228  
(60%) 
2 Did you enjoy sex this month? 283/366 
(77%) 
107/131 
(82%) 
3637/4892 
(74%) 
104/139 
(75%) 
4665/6228  
(75%) 
3 In general were you too tired to have sex? 70/363 
(19%) 
22/129 
(17%) 
1146/4873  
(24%) 
41/138 
(30%) 
1296/6208 
 (21%) 
4 Did you desire to have sex with your partner? 257/367 
(70%) 
91/131 
(69%) 
3219/4891  
(66%) 
84/138 
(61%) 
4141/6232  
(66%) 
5 During sex, how frequently did you notice dryness of your 
vagina this month? 
128/366 
(35%) 
47/131 
(36%) 
1658/4881  
(34%) 
54/140 
(39%) 
2089/6212  
(34%) 
6 Did you feel pain or discomfort during penetration? 68/366 
(19%) 
26/130 
(20%) 
798/4855  
(16%) 
25/139 
(18%) 
1048/6176  
(17%) 
7 In general did you feel satisfied after sexual activity this month? 283/363 
(78%) 
103/131 
(79%) 
3818/4877  
(78%) 
108/140 
(77%) 
4838/6191 
 (78%) 
8 How often did you engage in sexual activity this month? 203/368 
(55%) 
74/131 
(56%) 
2762/4903  
(56%) 
79/140 
(56%) 
3529/6247  
(56%) 
9 How did this frequency of sexual activity compare with what is 
usual for you? 
349/367 
(95%) 
127/131 
(97%) 
4629/4892  
(95%) 
131/139 
(94%) 
5917/6228 
(95%) 
10 Were you satisfied with the frequency of sexual activity this 
month? 
301/368 
(82%) 
107/131 
(82%) 
3943/4889  
(81%) 
110/139 
(79%) 
5009/6225 
 (80%) 
                                                          
2 Number of women who were sexually active, % 
3 Number of responses 
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Figure 1: Predicted pleasure score over time by group in the ES using a linear mixed effect model with a random intercept, 
including group indicator, group indicator by time interaction, age, trait anxiety and centre as explanatory variables 
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Figure 2: Odds ratios (95% confidence intervals) of “somewhat or much more” frequency of sexual activity (Habit) for 
women with high or medium levels of trait anxiety versus low levels of trait anxiety 
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Figure 3: Mean score differences (95% confidence intervals) of Discomfort and Pleasure amongst women with high or 
medium levels of trait anxiety and those with low levels
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Supplementary material 
Table S1. Random sample: for those who had sex (n=647) at baseline 
Group Pleasure range 
(0-18) 
Median, mean,  
Sd, IR 
Discomfort range 
(0-6) 
Median, mean,  
Sd, IR 
Habit range 
(0-3) 
Median, mean,  
Sd, IR 
Control   13.00, 12.33, 
4.23, 9 16 
5.00, 4.13, 
1.90, 3 6 
1.00, 1.00, 
0.33, 1 1 
Ultrasound (USS) 13.00, 12.28, 
3.99, 9 16 
5.00, 4.15, 
2.0, 13 6 
1.00, 1.02, 
0.32, 1 1 
Multimodal (MMS) 12.00, 11.82, 
3.94, 9 15 
5.00, 4.13, 
1.82, 3 6 
1.00, 0.99, 
0.32, 1 1 
 
 
Table S2. Events sample: for those who had sex (n=11314) at baseline 
Group Pleasure range 
(0-18) 
Median, mean,  
Sd, IR 
Discomfort range 
(0-6) 
Median, mean,  
Sd, IR 
Habit range 
(0-3) 
Median, mean,  
Sd, IR 
Ultrasound (USS) 12.00, 11.98, 
4.24, 9 16 
5.00, 4.23, 
1.85, 3 6 
1.00, 1.01, 
0.37, 1 1 
Multimodal (MMS) 12.00, 12.02, 
4.18, 9 16 
5.00, 4.23, 
1.87, 3 6 
1.00, 1.01, 
0.36, 1 1 
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Table S3. Random sample: sexual activity over time 
  
Control  Ultrasound (USS) Multimodal (MMS) 
group group group 
Prior to 
randomisation 
and baseline 
screening 
(n=755) 56% (n=283) 21% (n=301) 23% 
Sexually 
Active 
            
Yes 373 49.4% 134 47.3% 140 46.5% 
No 378 50.1% 144 50.9% 159 52.8% 
              
1st annual 
screen  
(n=683) 59% (n=214) 19% (n=262) 23% 
Sexually 
Active 
            
Yes 315 46.1% 82 38.3% 105 40.1% 
No 367 53.7% 132 61.7% 152 58.0% 
              
2nd annual (n=658) 60% (n=205) 19% (n=236) 22% 
Sexually 
Active 
            
Yes 281 42.7% 78 38.0% 92 39.0% 
No 372 56.5% 126 61.5% 139 58.9% 
              
3rd annual 
screen 
(n=615) 58% (n=213) 20% (n=228) 22% 
Sexually 
Active 
            
Yes 256 41.6% 78 36.6% 78 34.2% 
No 356 57.9% 135 63.4% 145 63.6% 
              
4th annual 
screen 
(n=576) 58% (n=196) 20% (n=221) 22% 
Sexually 
Active 
            
Yes 227 39.4% 72 36.7% 79 35.7% 
No 343 59.5% 124 63.3% 141 63.8% 
              
5th annual 
screen 
(n=548) 58% (n=188) 20% (n=205) 22% 
Sexually 
Active 
            
Yes 206 37.6% 66 35.1% 63 30.7% 
No 338 61.7% 120 63.8% 140 68.3% 
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Table S4. Events sample: sexual activity over time 
  
Ultrasound (USS) Multimodal (MMS) 
group group 
Prior to 
randomisation 
and baseline 
screening 
(n=10156) 44% (n=12810) 56% 
Sexually 
Active 
        
Yes 4971 48.9% 6343 49.5% 
No 5124 50.5% 6389 49.9% 
          
1st annual 
screen after 
event 
(n=5008) 52% (n=4641) 48% 
Sexually 
Active 
        
Yes 2209 44.1% 2004 43.2% 
No 2743 54.8% 2587 55.7% 
          
2nd annual 
screen 
(n=5659) 48% (n=6160) 52% 
Sexually 
Active 
        
Yes 2433 43.0% 2554 41.5% 
No 3171 56.0% 3543 57.5% 
          
3rd annual 
screen 
(n=5667) 44% (n=7215) 56% 
Sexually 
Active 
        
Yes 2333 41.2% 2836 39.3% 
No 3302 58.2% 4303 59.6% 
          
4th annual 
screen 
(n=5617) 41% (n=7957) 59% 
Sexually 
Active 
        
Yes 2162 38.5% 3032 38.1% 
No 3408 60.7% 4847 60.9% 
          
5th annual 
screen 
(n=5767) 40% (n=8730) 60% 
Sexually 
Active 
        
Yes 2149 37.3% 3088 35.4% 
No 3583 62.1% 5553 63.6% 
          
 
February 1st 2017 revision 
 
25 | P a g e  
 
Table S5: Number of participants experiencing repeat screens in the events sample  
year 1 2 or more 
Baseline 7507 697 
1 4046 1288 
2 2840 1232 
3 2577 1201 
4 1538 1075 
5 903 954 
 
 
 
